Official positions for FRAX (R) Clinical regarding biochemical markers from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX
Official positions for FRAX (R) Clinical regarding biochemical markers from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX
The best indirect evidence that increased bone turnover contributes to fracture risk is the fact that most of the proven therapies for osteoporosis are inhibitors of bone turnover. The evidence base that we can use biochemical markers of bone turnover in the assessment of fracture risk is somewhat less convincing. This relates to natural variability in the markers, problems with the assays, disparity in the statistical analyses of relevant studies and the independence of their contribution to fracture risk. More research is clearly required to address these deficiencies before biochemical markers might contribute a useful independent risk factor for inclusion in FRAX®.
biochemical markers, FRAX®, fracture risk, bone turnover
220-222
McCloskey, Eugene V.
2f057a16-3d4e-4597-80c7-6ce47f969c78
Vasikaran, Samuel
3ce2872a-4e12-4835-85a9-c48b734dfa28
Cooper, Cyrus
e05f5612-b493-4273-9b71-9e0ce32bdad6
July 2011
McCloskey, Eugene V.
2f057a16-3d4e-4597-80c7-6ce47f969c78
Vasikaran, Samuel
3ce2872a-4e12-4835-85a9-c48b734dfa28
Cooper, Cyrus
e05f5612-b493-4273-9b71-9e0ce32bdad6
McCloskey, Eugene V., Vasikaran, Samuel and Cooper, Cyrus
(2011)
Official positions for FRAX (R) Clinical regarding biochemical markers from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX.
Journal of Clinical Densitometry, 14 (3), .
(doi:10.1016/j.jocd.2011.05.008).
(PMID:21810528[)
Abstract
The best indirect evidence that increased bone turnover contributes to fracture risk is the fact that most of the proven therapies for osteoporosis are inhibitors of bone turnover. The evidence base that we can use biochemical markers of bone turnover in the assessment of fracture risk is somewhat less convincing. This relates to natural variability in the markers, problems with the assays, disparity in the statistical analyses of relevant studies and the independence of their contribution to fracture risk. More research is clearly required to address these deficiencies before biochemical markers might contribute a useful independent risk factor for inclusion in FRAX®.
This record has no associated files available for download.
More information
Published date: July 2011
Keywords:
biochemical markers, FRAX®, fracture risk, bone turnover
Organisations:
Faculty of Medicine
Identifiers
Local EPrints ID: 199679
URI: http://eprints.soton.ac.uk/id/eprint/199679
ISSN: 1094-6950
PURE UUID: 322962e4-b7e5-425f-b41c-4924a10391d6
Catalogue record
Date deposited: 18 Oct 2011 11:47
Last modified: 18 Mar 2024 02:45
Export record
Altmetrics
Contributors
Author:
Eugene V. McCloskey
Author:
Samuel Vasikaran
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
